Fractyl Health (GUTS) EBT Margin (2023 - 2024)
Fractyl Health (GUTS) recorded quarterly EBT Margin of 816133.33% in Q4 2024, down 400.1% on a QoQ basis from 163192.86% in Q3 2024, and down 63730476.0% YoY from N/an in Q1 2024.
Powered by 
Analysis
Fractyl Health (GUTS) EBT Margin (2023 - 2024) Analysis & Trends
Fractyl Health (GUTS) has reported EBT Margin for 2 consecutive years, with 816133.33% the latest figure, recorded in Q4 2024.
- For the quarter ending Q4 2024, EBT Margin fell 63730476.0% year-over-year to 816133.33%; the trailing twelve-month figure through Dec 2024 stood at 96112.9% (down 5479957.0% YoY), and the FY2024 full-year result was 96112.9%, down 5479957.0% from the prior year.
- EBT Margin was 816133.33% for Q4 2024 at Fractyl Health, down from 163192.86% in the prior quarter.
- The five-year high for EBT Margin was 16279.17% in Q2 2023, with the low at 816133.33% in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 179.79 Bn | 174.18 Bn | 7.27 Bn | 12.10% |
| 2 | Intuitive Surgical | 127.69 Bn | 122.47 Bn | 1.96 Bn | 36.46% |
| 3 | Medtronic | 117.23 Bn | 108.41 Bn | 6.34 Bn | 18.13% |
| 4 | Stryker | 103.55 Bn | 100.07 Bn | 4.50 Bn | 23.74% |
| 5 | Boston Scientific | 63.24 Bn | 62.70 Bn | 3.85 Bn | 19.48% |
| 6 | Edwards Lifesciences | 49.97 Bn | 45.72 Bn | 1.35 Bn | 29.86% |
| 7 | Alcon | 32.83 Bn | 31.37 Bn | 1.68 Bn | -1.65% |
| 8 | Dexcom | 32.30 Bn | 30.35 Bn | 830.00 Mn | 24.27% |
| 9 | Steris | 20.73 Bn | 20.25 Bn | 684.20 Mn | 18.32% |
| 10 | Fractyl Health | 102.00 Mn | 102.00 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | -816,133.33% |
| Sep 30, 2024 | -163,192.86% |
| Jun 30, 2024 | -50,255.81% |
| Mar 31, 2024 | -61,951.52% |
| Dec 31, 2023 | -178,828.57% |
| Sep 30, 2023 | -37,908.33% |
| Jun 30, 2023 | -16,279.17% |
| Mar 31, 2023 | -233,800.00% |